Heart valve disease
Conditions
Interventions
Exposure group (induced by disodium phosphopropofol anesthesia) :None
non-exposure group (induced by propofol medium/long chain fat emulsion anesthesia):None
Sponsors
The First Affiliated Hospital of Guangxi Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients scheduled for elective heart valve replacement surgery; 2. ASA classification II-IV; 3. Cardiac function classification (NYHA) II-IV; 4. Aged 18-65 years, any gender; 5. Body mass index less than 30 kg/m^2; 6. Voluntarily participate in the study after understanding the purpose, methods, and related information of this research, and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Individuals allergic to or contraindicated for phosphorylated propofol disodium, opioids, medium/long-chain fat emulsions of propofol, or their components; 2. Patients with uncontrolled hypertension or poorly controlled hypertension; 3. Severe liver or kidney dysfunction (Child-Pugh C or eGFR <30 mL/min/1.73m^2); 4. Severe cerebrovascular diseases, endocrine disorders, or history of hematologic diseases; 5. Patients with psychiatric disorders, chronic alcoholism, or using benzodiazepines or opioids; 6. Patients with difficult airways: Mallampati grade III or higher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The maximum change rate of MAP during the induction period;Other hemodynamic indicators ;Anesthesia-related adverse reactions ; | — |
Countries
China
Contacts
Public ContactChen Yanhua
The First Affiliated Hospital of Guangxi Medical University
Outcome results
None listed